Sugammadex Review: Has Merck Finally Put Safety Concerns To Rest?
This article was originally published in The Pink Sheet Daily
Executive Summary
Adequacy of data on risks of hypersensitivity/anaphylaxis and cardiac dysrhythmia with neuromuscular blockade reversal agent are focus of FDA advisory committee review.